1.Turbid-phlegm is an important pathogenesis of restenosis after percutaneous transluminal coronary intervention.
Chinese Journal of Integrated Traditional and Western Medicine 2005;25(8):750-753
The occurrence rate of restenosis after percutaneous transluminal coronary intervention (PCI) was quite high. Traditional Chinese medicine (TCM) has been proved to have the effect in preventing and curing restenosis. In this article, turbid-phlegm was proved to be directly related with restenosis after PCI in aspects of coronary arteriography, blood lipid, blood viscosity, fibrolysis system, free radicals, plasma homocysteine, insulin resistance, etc. So it is one of the important pathogenetic factors of restenosis after PCI in TCM.
Angioplasty, Balloon, Coronary
;
Coronary Restenosis
;
drug therapy
;
etiology
;
Diagnosis, Differential
;
Drugs, Chinese Herbal
;
therapeutic use
;
Humans
;
Medicine, Chinese Traditional
;
Myocardial Infarction
;
drug therapy
;
therapy
;
Phytotherapy
2.Efficacy and safety of implantation of multiple drug-eluting stents.
Qiang FU ; Zhi-Liang LI ; Hong-Chao WU
Journal of Southern Medical University 2008;28(1):110-112
OBJECTIVETo assess the efficacy and safety of implantation of multiple drug-eluting stents.
METHODSA retrospective study of 151 cases was conducted, including 34 with implantation of at least 3 drug-eluting stents in the coronary artery (MS group), 53 with implantation of two stents (TS group), and 64 with a single stent (OS group). The incidence of major adverse cardiovascular event (MACE) and restenosis was evaluated.
RESULTSNo significant difference was found between the 3 groups in the incidence of MACE or in the stent thrombosis rate 30 days after the implantation. Follow-up of the patients for 6 months still showed comparable restenosis rate and MACE incidence between the 3 groups.
CONCLUSIONImplantation of multiple drug-eluting stents does not increase the risk of restenosis or MACE, and has comparable safety and efficacy with implantation of single and two stents.
Angioplasty, Balloon, Coronary ; adverse effects ; methods ; Coronary Artery Disease ; therapy ; Coronary Restenosis ; diagnosis ; etiology ; Drug-Eluting Stents ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome
3.Effects of Combined Therapy with Ezetimibe Plus Simvastatin After Drug-Eluting Stent Implantation in a Porcine Coronary Restenosis Model.
Jung Sun CHO ; Myung Ho JEONG ; Doo Sun SIM ; Young Joon HONG ; Kyung Seob LIM ; Jung Ha KIM ; Hyoung Doo KIM ; Ju Yeal BAEK ; Hee Jeoung YOON ; Sung Ho HER ; Seung Won JIN ; Ju Han KIM ; Youngkeun AHN ; Jeong Gwan CHO ; Jong Chun PARK ; Jung Chaee KANG
Journal of Korean Medical Science 2010;25(5):716-722
The aim of this study was to examine the anti-proliferative and anti-inflammatory effects of ezetimibe/simvastatin (E/S) after drug-eluting stent (DES) implantation in a porcine coronary restenosis model. Pigs were randomized into two groups in which the coronary arteries (23 pigs) had DES. Stents were deployed with oversizing (stent/artery ratio 1.3:1) in porcine coronary arteries. Fifteen pigs were taken 10/20 mg of E/S and eight pigs were not taken E/S. Histopathologic analysis was assessed at 28 days after stenting. In neointima, most inflammatory cells were lymphohistiocytes. Lymphohistiocyte count was not different between two groups (337+/-227 vs. 443+/-366 cells, P=0.292), but neointima area was significantly smaller (1.00+/-0.49 mm2 vs. 1.69+/-0.98 mm2, P=0.021) and percent area stenosis was significantly lower (23.3+/-10% vs. 39+/-19%, P=0.007) in E/S group compared with control group. There were no significant differences in fibrin score (1.99+/-0.79 vs. 1.81+/-0.88, P=0.49), endothelial score (1.75+/-0.66 vs. 1.80+/-0.59, P=0.79), and the percent of endothelium covered lumen (43+/-21% vs. 45+/-21%, P=0.84) between E/S group and control group. Combined therapy with ezetimibe and simvastatin inhibits neointimal hyperplasia, but does not inhibit inflammatory infiltration and arterial healing after DES implantation in a porcine coronary restenosis model.
Animals
;
Anticholesteremic Agents/administration & dosage
;
Azetidines/*administration & dosage
;
Coronary Restenosis/diagnosis/drug therapy/*etiology
;
*Disease Models, Animal
;
Drug Combinations
;
Drug Implants/administration & dosage
;
Drug-Eluting Stents/*adverse effects
;
Female
;
Graft Occlusion, Vascular/diagnosis/*drug therapy/*etiology
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage
;
Simvastatin/*administration & dosage
;
Swine
;
Treatment Outcome